Bootstrapped medical-grade skincare brand Ceuticoz is aiming to scale revenues to ₹40 crore this fiscal year, up from ₹26–27 crore in the previous year, as it deepens its science-led portfolio across India and accelerates expansion into international markets.
Founder Sukhbir Singh Chimni said the company has remained EBITDA-positive since inception and is already ahead of its growth targets this year. With strong momentum in recent months, Ceuticoz expects to maintain a steady upward trajectory and is targeting ₹100 crore in revenue within the next two to three years.
India continues to contribute more than 70% of overall revenue and remains the brand’s primary growth engine. The company is now focusing on expanding its dermatologist-led distribution model into tier-2 and tier-3 towns, where it sees significant potential for pharmaceutical-grade skincare products. Chimni noted that high-quality, medical-grade skincare is often perceived as expensive in smaller towns, a perception the brand aims to change by making such products more accessible.
Internationally, the Gulf region has emerged as a key priority. Ceuticoz plans to showcase its portfolio at Dubai Derma and is building channel partnerships across the GCC markets. Countries such as Iraq, Vietnam, Nepal and Thailand are already contributing traction, while the brand has recently entered Canada, targeting dermatologists, aestheticians and clinical nurses through a professional-channel strategy similar to its India playbook.
On the product front, Ceuticoz has introduced seven baby care products and is preparing to launch four high-potency ampoules next quarter. The ampoules, designed to deliver concentrated active ingredients, are expected to strengthen the brand’s positioning in clinical skincare.
Sourcing ingredients from over 23 countries, Ceuticoz anticipates annual growth of around 35% over the next few years. While the company is not actively seeking funding, Chimni said it remains open to partnering with strategic investors who can add value beyond capital.
